{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:22:40Z","timestamp":1790468560735,"version":"4.1.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T00:00:00Z","timestamp":1447200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0138537","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T18:44:21Z","timestamp":1447267461000},"page":"e0138537","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["1H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis"],"prefix":"10.1371","volume":"10","author":[{"given":"Roberta","family":"Priori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Scrivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Valesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Manetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"key":"ref1","first-page":"2208","article-title":"Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5-year followup of a prospective double blind placebo controlled study","volume":"22","author":"C Egsmose","year":"1995","journal-title":"J Rheumatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \u201csecond-line\u201d antirheumatic drugs: a randomized, controlled trial","volume":"124","author":"A van der Heide","year":"1996","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"M Boers","year":"1997","journal-title":"Lancet"},{"key":"ref4","first-page":"623","article-title":"Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study","volume":"27","author":"E Tsakonas","year":"2000","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.10083","article-title":"COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention","volume":"46","author":"RBM Landewe\u2019","year":"2002","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/ard.2009.108027","article-title":"Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis","volume":"69","author":"LH van Tuyl","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"JS Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"A Finckh","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"CL Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref10","first-page":"CD007848","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","volume":"4","author":"JA Singh","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ncprheum0050","article-title":"Challenges of predicting treatment response in patients with rheumatoid arthritis","volume":"1","author":"D Aletaha","year":"2005","journal-title":"Nat Clin Pract Rheumatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: current biologic agents and future prospects in RA","volume":"9","author":"EH Choy","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/4551054a","article-title":"Metabonomics","volume":"445","author":"JK Nicholson","year":"2008","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11306-007-0081-3","article-title":"Proposed minimum reporting standards for data analysis in metabolomics","volume":"3","author":"R Goodacre","year":"2007","journal-title":"Metabolomics"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.autrev.2013.04.002","article-title":"Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy","volume":"12","author":"R Priori","year":"2013","journal-title":"Autoimmun Rev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11882-014-0445-5","article-title":"Metabolomics approach in allergic and rheumatic diseases","volume":"14","author":"R Scrivo","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/annrheumdis-2014-206618","article-title":"Metabolomics for rheumatic diseases: has the time come?","volume":"74","author":"L Semerano","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/ard.50.6.366","article-title":"Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis","volume":"50","author":"S Rantap\u00e4\u00e4-Dahlqvist","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0009-8981(98)00200-9","article-title":"Nuclear magnetic resonance studies of synovial fluids from patients with rheumatoid arthritis and osteoarthritis","volume":"281","author":"S Meshitsuka","year":"1999","journal-title":"Clin Chim Acta"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1021\/pr1002774","article-title":"<sup>1<\/sup>H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients","volume":"9","author":"MB Lauridsen","year":"2010","journal-title":"J Proteome Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1186\/ar3243","article-title":"Diagnostic properties of metabolic perturbations in rheumatoid arthritis","volume":"13","author":"RK Madsen","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0961203311418707","article-title":"1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus","volume":"20","author":"X Ouyang","year":"2011","journal-title":"Lupus"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.joca.2011.10.010","article-title":"Global metabolic profiling of human osteoarthritic synovium","volume":"20","author":"SB Adams Jr","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3892\/etm.2012.567","article-title":"(1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis","volume":"4","author":"Z Wang","year":"2012","journal-title":"Exp Ther Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e37210","DOI":"10.1371\/journal.pone.0037210","article-title":"Metabolic disturbances associated with systemic lupus erythematosus","volume":"7","author":"T Wu","year":"2012","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/art.37921","article-title":"Metabolic profiling predicts response to antitumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis","volume":"65","author":"SR Kapoor","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38021","article-title":"The impact of inflammation on metabolomic profiles in patients with arthritis","volume":"65","author":"SP Young","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"ME Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"JM Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"ref30","first-page":"1594","article-title":"for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"PE Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"ME Weinblatt","year":"2003","journal-title":"Arthritis Rheumatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"EC Keystone","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"EW St Clair","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheumatol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pgen.1002215","article-title":"Discovery of sexual dimorphisms in metabolic and genetic biomarkers","volume":"7","author":"K Mittelstrass","year":"2011","journal-title":"PLoS Genet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1021\/ac0708588","article-title":"Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles","volume":"79","author":"CM Slupsky","year":"2007","journal-title":"Anal Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"JF Fries","year":"1980","journal-title":"Arthritis Rheumatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"AM van Gestel","year":"1998","journal-title":"Arthritis Rheumatol"},{"key":"ref39","first-page":"R1697","article-title":"Quantitative modeling and biology: the multivariate approach","volume":"266","author":"R Benigni","year":"1994","journal-title":"Am J Physiol"},{"key":"ref40","article-title":"Investigating sources of variability in metabolomic data in the EPIC study: the Principal Component Partial R-square (PC-PR2) method","author":"A Fages","journal-title":"Metabolomics"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/ker010","article-title":"The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study","volume":"50","author":"R Klaasen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"ref42","first-page":"494","article-title":"Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data","volume":"29","author":"Y Yazici","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/annrheumdis-2011-200379","article-title":"The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study","volume":"71","author":"M van den Broek","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3109\/s10165-012-0822-7","article-title":"Shorter disease duration is important for tocilizumab to achieve Boolean remission","volume":"23","author":"Y Kawasaki","year":"2013","journal-title":"Mod Rheumatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38671","article-title":"Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial","volume":"66","author":"J Sellam","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10067-014-2538-x","article-title":"Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker","volume":"33","author":"L Siemons","year":"2014","journal-title":"Clin Rheumatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/ard.2006.063834","article-title":"Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan","volume":"66","author":"T Matsui","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis","volume":"68","author":"C Potter","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0014-5793(93)81508-W","article-title":"An investigation of the abnormal metabolic status of synovial fluid from patients with rheumatoid arthritis by high field proton nuclear magnetic resonance spectroscopy","volume":"317","author":"D Naughton","year":"1993","journal-title":"FEBS Lett"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0925-4439(99)00020-4","article-title":"Examination of the metabolic status of rat air pouch inflammatory exudate by high field proton NMR spectroscopy","volume":"1454","author":"A Claxson","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1021\/pr070123j","article-title":"An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy","volume":"6","author":"AM Weljie","year":"2007","journal-title":"J Proteome Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0138537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T12:56:02Z","timestamp":1567342562000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0138537"}},"subtitle":[],"editor":[{"given":"Paul C.","family":"Driscoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0138537","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,11]]}}}